Skip to main content

Advertisement

Table 3 Characteristics of discontinued users

From: The real-world patient experience of fingolimod and dimethyl fumarate for multiple sclerosis

Characteristic, n (%) DF (N = 32) DDMF (N = 59)
When did you start therapy?, n (%)
 Within the last 7 days 0 (0.0 %) 1 (1.7 %)
 Between 8 and 30 days ago 0 (0.0 %) 5 (8.5 %)
 Between 31 and 60 days ago 1 (3.1 %) 2 (3.4 %)
 More than 60 days ago 31 (96.9 %) 51 (86.4 %)
When did you stop therapy?, n (%)
 Within the last 7 days 0 (0.0 %) 2 (3.4 %)
 Between 8 and 30 days ago 1 (3.1 %) 14 (23.7 %)
 Between 31 and 60 days ago 3 (9.4 %) 8 (13.6 %)
 More than 60 days ago 28 (87.5 %) 35 (59.3 %)
Reasons stopped taking therapya, n (%)
 Side effects 14 (43.8 %) 46 (78.0 %)
 Doctor advice 8 (25.0 %) 14 (23.7 %)
 Lack of effectiveness in treating MS 8 (25.0 %) 13 (22.0 %)
 Concerns regarding the safety 5 (15.6 %) 5 (8.5 %)
 Struggled to take therapy as prescribed 1 (3.1 %) 3 (5.1 %)
 Financial reasons 1 (3.1 %) 2 (3.4 %)
 Did not want to take oral treatment 0 (0.0 %) 1 (1.7 %)
 Changes to health plan benefits 1 (3.1 %) 0 (0.0 %)
 Another reason not listed 6 (18.8 %) 7 (11.9 %)
Main reason stopped taking therapy, n (%)
 Side effects 15 (46.9 %) 40 (67.8 %)
 Lack of effectiveness in treating MS 8 (25.0 %) 9 (15.3 %)
 Doctor advice 2 (6.3 %) 3 (5.1 %)
 Concerns regarding safety 2 (6.3 %) 0 (0.0 %)
 Financial reasons 0 (0.0 %) 1 (1.7 %)
 Another reason not listed 5 (15.6 %) 6 (10.2 %)
Who mainly made decision to discontinue therapy?, n (%)
 Mainly my decision 9 (28.1 %) 24 (40.7 %)
 Mainly doctor decision 7 (21.9 %) 8 (13.6 %)
 Joint decision 16 (50.0 %) 27 (45.8 %)
  1. aParticipants could select more than one response